Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 9.27 and a target value of HKD 15.00 [3][21]. Core Insights - The company achieved its first annual profit in 2025, with revenue of RMB 803 million, a year-on-year increase of 201.2%, and a net profit of RMB 135 million, compared to a loss of RMB 1.515 billion in the previous year [7][8]. - The rapid revenue growth is driven by the drug discovery solutions segment, which generated RMB 538 million in revenue, up 418.9% year-on-year, and the AI4S smart solutions segment, which earned RMB 265 million, a 62.6% increase [7][8]. - The company is enhancing its AI4S capabilities and accelerating its global expansion, aiming to establish a platform company that can replicate its model across various industries, including pharmaceuticals, new materials, and consumer health [10][19]. Financial Projections - Revenue projections for 2026 to 2028 are RMB 1.137 billion, RMB 1.535 billion, and RMB 2.026 billion, respectively, representing year-on-year growth rates of 42%, 35%, and 32% [16][21]. - The drug discovery solutions segment is expected to continue driving growth, with projected revenues of RMB 753 million, RMB 1.017 billion, and RMB 1.352 billion for the same period [15][21]. - The AI4S smart solutions segment is also anticipated to grow, with expected revenues of RMB 384 million, RMB 518 million, and RMB 674 million from 2026 to 2028 [15][21]. Business Model and Strategy - The company is transitioning from a single project service model to a platform licensing model, which includes milestone payments and revenue sharing, enhancing its long-term commercial value [9][10]. - The company has established high-value collaborations with international pharmaceutical companies, indicating a shift towards a more integrated and scalable business model [9][10]. - The report highlights the company's strong cash reserves, which will support its overseas expansion and technology acquisitions, further solidifying its market position [10][19].
晶泰控股（02228）：25年实现盈利，平台进入规模化兑现阶段